Arcutis Biotherapeutics President and CEO Todd Watanabe sold 4,375 shares on August 3, 2026, in a non-discretionary transaction to satisfy tax withholding obligations tied to the vesting of restricted stock units. The sale, valued at $114,275 based on a weighted average price of $26.12, left Watanabe with 950,337 total shares worth $24.65 million at the market close. The company reported second-quarter results on August 5, with roflumilast product Zoryve revenue growing 59% to $129.9 million and net income reaching $15 million, or $0.11 per share, compared to a net loss of $15.9 million a year earlier. Arcutis raised its full-year 2026 net product sales guidance to between $525 million and $540 million and received FDA approval to expand Zoryve's indication to treat plaque psoriasis in children as young as two.
Arcutis Biotherapeutics IncQ2 beat with Zoryve revenue up 59% and first net income, plus raised guidance and FDA approval for pediatric indication.
